Natural killer cell immunomodulation: Targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy

Frontiers in Immunology

Volumn 6, Issue DEC, 2015, Pages

  Chester, Cariad ^a   Fritsch, Katherine ^a   Kohrt, Holbrook E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive cell therapy; Cancer vaccines; Checkpoint blockade; Immunotherapy; Monoclonal antibody; Natural killer cells

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LYSIS; NATURAL KILLER CELL; TRANSFORMED CELL; TUMOR ESCAPE;

EID: 84954202043     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00601     Document Type: Review

References (109)

1. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene (2008) 27:5932-43. doi: 10.1038/onc.2008.267.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9:503-10. doi:10.1038/ni1582.
3. Caligiuri MA. Human natural killer cells. Blood (2008) 112:461-9. doi:10.1182/blood-2007-09-077438.
4. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood (2001) 97:3146-51. doi:10.1182/blood.V97.10.3146.
5. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol (2007) 179:89-94. doi:10.4049/jimmunol.179.1.89.
6. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, et al. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 178:4947-55. doi:10.4049/jimmunol.178.8.4947.
7. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2011) 108:728-32. doi:10.1073/pnas.1012356108.
8. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 7:329-39. doi:10.1038/nri2073.
9. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 17:678-89. doi:10.1158/1078-0432.CCR-10-2173.
10. Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R, et al. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) (2012) 90:55-66. doi:10.1007/s00109-011-0806-7.
11. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 71:5412-22. doi:10.1158/0008-5472.CAN-10-4179.
12. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet (2000) 356:1795-9. doi:10.1016/S0140-6736(00)03231-1.
13. Borrego F. The first molecular basis of the "missing self" hypothesis. J Immunol (2006) 177:5759-60. doi:10.4049/jimmunol.177.9.5759.
14. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol (2005) 174:6566-9. doi:10.1038/319675a0.
15. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of. Ly-49 (1992) 358:66-70. doi:10.1038/358066a0.
16. Ljunggren HG, Kärre K. In search of the missing self: MHC molecules and NK cell recognition. Immunol Today (1990) 11:237-44. doi:10.1016/0167-5699(90)90097-S.
17. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 31:227-58. doi:10.1146/annurev-immunol-020711-075005.
18. Clark R, Griffiths GM. Lytic granules, secretory lysosomes and disease. Curr Opin Immunol (2003) 15:516-21. doi:10.1016/S0952-7915(03)00113-4.
19. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol (2003) 3:361-70. doi:10.1038/nri1083.
20. Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, Martinvalet D, et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol (2011) 12:770-7. doi:10.1038/ni.2050.
21. Mentlik AN, Sanborn KB, Holzbaur EL, Orange JS. Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. Mol Biol Cell (2010) 21:2241-56. doi:10.1091/mbc.E09-11-0930.
22. Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev (2010) 235:105-16. doi:10.1111/j.0105-2896.2010.00908.x.
23. Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 13:95-109. doi:10.1016/S1359-6101(01)00038-7.
24. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9:361-71. doi:10.1038/nrc2628.
25. Higuchi M, Nagasawa K, Horiuchi T, Oike M, Ito Y, Yasukawa M, et al. Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation - characterization of membrane TNF-alpha. Clin Immunol Immunopathol (1997) 82:133-40. doi:10.1006/clin.1996.4291.
26. Takeda K, Iwamoto S, Sugimoto H, Takuma T, Kawatani N, Noda M, et al. Identity of differentiation inducing factor and tumour necrosis factor. Nature (1986) 323:338-40. doi:10.1038/323338a0.
27. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 4:511-27. doi:10.2217/imt.12.38.
28. Rodríguez J, Zarate R, Bandres E, Boni V, Hernández A, Sola JJ, et al. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer (2012) 48:1774-80. doi:10.1016/j.ejca.2012.01.007.
29. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99:754-8. doi:10.1182/blood.V99.3.754.
30. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 26:1789-96. doi:10.1200/JCO.2007.14.8957.
31. Rajasekaran N, Chester C, Yonezawa A, Zhao X, et al. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Biologics (2015) 9:35-43. doi:10.2147/ITT.S61292.
32. Márquez ME, Millet C, Stekman H, Conesa A, Deglesne PA, Toro F, et al. CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells. Cell Immunol (2010) 264:86-92. doi:10.1016/j.cellimm.2010.05.002.
33. Walzer T, Dalod M, Vivier E, Zitvogel L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther (2005) 5(Suppl 1):S49-59. doi:10.1517/14712598.5.1.S49.
34. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol (1994) 12:735-73. doi:10.1146/annurev.iy.12.040194.003511.
35. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 188:2375-80. doi:10.1084/jem.188.12.2375.
36. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol (2005) 42:501-10. doi:10.1016/j.molimm.2004.07.034.
37. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 26:239-57. doi:10.1038/bjc.1972.33.
38. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol (2002) 12:309-15. doi:10.1016/S1044-579X(02)00017-2.
39. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 7:94-100. doi:10.1038/83416.
40. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci (2004) 95:777-83. doi:10.1111/j.1349-7006.2004.tb02181.x.
41. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 39:1462-75. doi:10.1016/j.biocel.2007.02.007.
42. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 8:782-98. doi:10.1038/nrc2465.
43. De Miguel D, Gallego-Lleyda A, Galan-Malo P, Rodriguez-Vigil C, Marzo I, Anel A, et al. Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells. Clin Transl Oncol (2015) 17:657-67. doi:10.1007/s12094-015-1295-x.
44. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2013) 32:1341-50. doi:10.1038/onc.2012.164.
45. Jacobs B, Ullrich E. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? Curr Med Chem (2012) 19:1771-9. doi:10.2174/092986712800099857.
46. Kaifu T, Escalière B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci (2011) 68:3531-9. doi:10.1007/s00018-011-0802-7.
47. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 9:568-80. doi:10.1038/nri2604.
48. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol (2013) 4:69. doi:10.3389/fimmu.2013.00069.
49. Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol (2003) 33:3439-47. doi:10.1002/eji.200324533.
50. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 19:197-223. doi:10.1146/annurev.immunol.19.1.197.
51. Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G, et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol (2001) 31:233-42. doi:10.1002/1521-4141(200101)31:1<233::AID-IMMU233>3.3.CO;2-W.
52. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer (2009) 9:186. doi:10.1186/1471-2407-9-186.
53. Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, et al. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol (2012) 189:5037-46. doi:10.4049/jimmunol.1201321.
54. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 17:700-7. doi:10.1038/nm.2366.
55. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med (2015) 7:283ra55. doi:10.1126/scitranslmed.aaa2327.
56. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 31:413. doi:10.1146/annurev-immunol-032712-095951.
57. Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res (2015) 3:575-82. doi:10.1158/2326-6066.CIR-15-0098.
58. Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T, et al. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother (2009) 58:1245-55. doi:10.1007/s00262-008-0643-x.
59. García-Cuesta EM, López-Cobo S, álvarez-Maestro M, Esteso G, Romera-Cárdenas G, Rey M, et al. NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation. Front Immunol (2015) 6:284. doi:10.3389/fimmu.2015.00284.
60. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419:734-8. doi:10.1038/nature01112.
61. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature (2007) 447:482-6. doi:10.1038/nature05768.
62. Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science (2015) 348:136-9. doi:10.1126/science.1258867.
63. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol (1993) 151:60-70.
64. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol (1999) 29:1676-83. doi:10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y.
65. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood (2006) 107:159-66. doi:10.1182/blood-2005-04-1351.
66. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol (2014) 92:237-44. doi:10.1038/icb.2013.95.
67. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity (1996) 4:573-81. doi:10.1016/S1074-7613(00)70060-4.
68. Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol (2004) 16:513-21. doi:10.1016/j.ceb.2004.07.007.
69. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood (2006) 107:1491-6. doi:10.1182/blood-2005-04-1684.
70. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 64:9180-4. doi:10.1158/0008-5472.CAN-04-2682.
71. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 183:4921-30. doi:10.4049/jimmunol.0901226.
72. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466.
73. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev (2009) 229:12-26. doi:10.1111/j.1600-065X.2009.00770.x.
74. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677-704. doi:10.1146/annurev.immunol.26.021607.090331.
75. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1:1223-5. doi:10.4161/onci.21335.
76. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol (2002) 20:217-51. doi:10.1146/annurev.immunol.20.092501.134942.
77. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295:2097-100. doi:10.1126/science.1068440.
78. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood (2005) 105:4878-84. doi:10.1182/blood-2004-12-4825.
79. Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood (2001) 97:3132-7. doi:10.1182/blood.V97.10.3132.
80. Garcia CA, Robinson J, Guethlein LA, Parham P, Madrigal JA, Marsh SG. Human KIR sequences 2003. Immunogenetics (2003) 55:227-39. doi:10.1007/s00251-003-0572-y.
81. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 120:4317-23. doi:10.1182/blood-2012-06-437558.
82. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 120:4324-33. doi:10.1182/blood-2012-06-438028.
83. Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab-but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol (2014) 192:5618-24. doi:10.4049/jimmunol.1400288.
84. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2014) 123:678-86. doi:10.1182/blood-2013-08-519199.
85. Braud VM, Allan DS, O'Callaghan CA, Söderström K. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 391:795-9. doi:10.1038/35869.
86. Brooks AG, Borrego F, Posch PE, Patamawenu A, Scorzelli CJ, Ulbrecht M, et al. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol (1999) 162:305-13.
87. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol (2008) 32:633-41. doi:10.3892/ijo.32.3.633.
88. Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simões RT, et al. Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol (2011) 26:1487-97. doi:10.1016/j.semcancer.2012.03.003.
89. Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, et al. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol (2013) 4:19. doi:10.3389/fimmu.2013.00019.
90. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 121:3609-22. doi:10.1172/JCI45816.
91. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A (1989) 86:1963-7. doi:10.1073/pnas.86.6.1963.
92. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 186:47-55. doi:10.1084/jem.186.1.47.
93. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3:682-5. doi:10.1038/nm0697-682.
94. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol (1998) 190:167-72. doi:10.1006/cimm.1998.1396.
95. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol (2002) 169:4230-6. doi:10.4049/jimmunol.169.8.4230.
96. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2011) 117:2423-32. doi:10.1182/blood-2010-08-301945.
97. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 124:2668-82. doi:10.1172/JCI73014.
98. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R, Pishvaian MJ, et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer [abstract]. J Clin Oncol (2014) 32:3007. doi:10.1007/s00262-012-1237-1.
99. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol (2010) 28:57-78. doi:10.1146/annurev-immunol-030409-101243.
100. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 118:1165-75. doi:10.1172/JCI33583.
101. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 164:2160-9. doi:10.4049/jimmunol.164.4.2160.
102. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 73:7189-98. doi:10.1158/0008-5472.CAN-12-4174.
103. Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Crittenden M, Lary S, et al. Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis. J Immunother Cancer (2013) 1:1-1. doi:10.1186/2051-1426-1-S1-P255.
104. Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects. Immunology (2014) 141:483-9. doi:10.1111/imm.12224.
105. Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, et al. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol (2008) 180:3739-45. doi:10.4049/jimmunol.180.6.3739.
106. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2002) 3:83-90. doi:10.1038/ni746.
107. Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res (2012) 18:3812-21. doi:10.1158/1078-0432.CCR-11-3308.
108. He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol (2013) 191:4174-83. doi:10.4049/jimmunol.1300409.
109. Ansell SM, Northfelt DW, Flinn I, Burris HA, et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. ASCO Annual Meeting (2014). Available from: http://meetinglibrary.asco.org/content/132758-144.